Cancer Immunotherapy Guidelines Oversight Committee
The Cancer Immunotherapy Guidelines Oversight Committee oversees the development of new clinical practice guidelines and updates for existing guidelines that provide guidance on the appropriate treatment algorithms and recommended administration of FDA-approved cancer immunotherapies as well as mitigating and managing adverse events.
The committee determines the policies and protocols for the general guideline development process as well as the standards the expert panels must meet to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making leading to optimal patient care.
The committee also provides strategic insights into the existing dissemination efforts such as guideline education and mobile app development as well as envisions and informs new dissemination tactics.